Ga-FAPI-46
Phase 2Small molecule
Ga-FAPI-46 is one of 50 small molecule programs targeting Breast Carcinoma. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
88 competitors in Breast Carcinoma
#DrugCompanyPhaseTrials
1Afinitor
NovartisApproved
Tagrisso
AstraZenecaApproved
Ixempra
RR-Pharm
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Zocor
OOrganon and Co
Approved
Zoladex
TTerSera Therapeutics LLC
Approved
Taxol
TevaPhase 3
Tecentriq
RochePhase 3
Imfinzi
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ga-FAPI-46. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversität Münster